×
About 74 results

ALLMedicine™ Severe Chronic Neutropenia Center

Research & Reviews  35 results

Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-inter...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845007
Blood Saettini F, Poli C et. al.

Sep 9th, 2020 - Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobul...

Registries for study of nonmalignant hematological diseases: the example of the Severe ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236759
Current Opinion in Hematology; Dale DC, Bolyard AA et. al.

Nov 25th, 2019 - Registries provide 'real world' perspectives on the natural history and outcomes for many clinical conditions. The purpose of this review is to identify registries for nonmalignant hematological disease and to describe the operation of a successfu...

Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis pa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396443
Orphanet Journal of Rare Diseases; Galli J, Pinelli L et. al.

Mar 1st, 2019 - Warts Hypogammaglobulinemia Immunodeficiency Myelokathexis (WHIM) syndrome is a primary immunodeficiency characterized by recurrent bacterial infections, severe chronic neutropenia, with lymphopenia, monocytopenia and myelokathexis which is caused...

FDA approves biosimilar filgrastim
https://www.mdedge.com/hematology-oncology/article/184832/anemia/fda-approves-biosimilar-filgrastim
HT Staff

Jul 22nd, 2018 - Photo by Bill Branson Vials of drug The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malig.

see more →

Clinicaltrials.gov  37 results

Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-inter...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845007
Blood Saettini F, Poli C et. al.

Sep 9th, 2020 - Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an early termination of B-cell development. We here investigated 3 novel patients, including the first known adult, from unrelated families with agammaglobul...

Registries for study of nonmalignant hematological diseases: the example of the Severe ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236759
Current Opinion in Hematology; Dale DC, Bolyard AA et. al.

Nov 25th, 2019 - Registries provide 'real world' perspectives on the natural history and outcomes for many clinical conditions. The purpose of this review is to identify registries for nonmalignant hematological disease and to describe the operation of a successfu...

Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis pa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396443
Orphanet Journal of Rare Diseases; Galli J, Pinelli L et. al.

Mar 1st, 2019 - Warts Hypogammaglobulinemia Immunodeficiency Myelokathexis (WHIM) syndrome is a primary immunodeficiency characterized by recurrent bacterial infections, severe chronic neutropenia, with lymphopenia, monocytopenia and myelokathexis which is caused...

FDA approves biosimilar filgrastim
https://www.mdedge.com/hematology-oncology/article/184832/anemia/fda-approves-biosimilar-filgrastim
HT Staff

Jul 22nd, 2018 - Photo by Bill Branson Vials of drug The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malig.

see more →

News  2 results

FDA approves biosimilar filgrastim
https://www.mdedge.com/hematology-oncology/article/184832/anemia/fda-approves-biosimilar-filgrastim
HT Staff

Jul 22nd, 2018 - Photo by Bill Branson Vials of drug The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malig.

First Biosimilar, a Filgrastim Copycat, Is Approved
https://www.medpagetoday.com/hematologyoncology/hematology/50356

Mar 6th, 2015 - WASHINGTON -- The FDA has approved Sandoz's copy of filgrastim, the first so-called biosimilar drug to win the agency's OK. To be sold as Zarxio with a generic name of filgrastim-sndz, the product will compete against Amgen's original drug, Neupog...

see more →